Compare Adaptive Biotechnologies Corp (ADPT) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dollar General Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Dollar General Corp. trades at $115 (market cap $25.46B). The key difference: Dollar General Corp. is far larger — about 7.6× Adaptive Biotechnologies Corp's market cap, and Dollar General Corp. pays a 2.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DG | |
|---|---|---|
Market Cap | $3.33B | $25.46B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $156.26 |
52-Week Low | $10.24 | $95.94 |
Enterprise Value | $3.19B | $39.91B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Dollar General (DG) trades at $115.43, down 2.32% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.00 surpassing the $1.89 estimate. Fundamentals reveal steady revenue growth to $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive cash flow trends and a manageable debt-to-asset ratio of 20.03% support financial health.
The investment outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating with a $128.91 price target, implying ~12% upside. Key opportunities include margin expansion initiatives and the DG Media Network, while risks involve consumer spending sensitivity and competitive pressures. The current valuation at a P/E of 16.45 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
